Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies reports developments tied to its role as a supplier of ion implantation systems and process applications for semiconductor manufacturing. Company updates commonly cover quarterly results, demand trends across memory, power, compound semiconductor and mature-node markets, and the performance of its customer support and installed-base services business.
News also includes technical participation at semiconductor industry conferences, lifecycle support for Purion-based implant platforms, sustainability targets for greenhouse gas emissions, investor-conference activity and governance changes such as finance leadership transitions. The recurring business context centers on equipment used in integrated-circuit fabrication and aftermarket services including spare parts, upgrades, maintenance and training.
Axcelis Technologies (NASDAQ: ACLS) reported strong Q2 2024 financial results, with revenue of $256.5 million, up from $252.4 million in Q1. The company's operating margin was 20.6%, with diluted EPS of $1.55. Gross margin decreased slightly to 43.8% from 46.0% in Q1. CEO Russell Low highlighted better-than-expected conversion of evaluation units and robust demand in the Power segment, particularly in silicon carbide. For Q3 2024, Axcelis expects revenues of approximately $255 million and EPS of about $1.43. The company anticipates revenue in the second half of 2024 to be slightly better than the first half, with momentum building into 2025.
Axcelis Technologies (Nasdaq: ACLS), a leading supplier of ion implantation solutions for the semiconductor industry, has announced the timing for its second quarter 2024 financial results. The company will release its Q2 2024 results on Wednesday, July 31, 2024, at 4:00 p.m. ET. Following this, Axcelis will host a conference call to discuss these results on Thursday, August 1, 2024, at 8:30 a.m. ET.
Interested parties can access the call via an audio webcast on the Investors page of Axcelis' website or by registering as a participant through a provided link. The webcast replay will be available for 30 days after the call.
Axcelis Technologies, a key supplier in the semiconductor industry, announced preliminary Q2 2024 financial results ahead of an investor event. The company expects revenue to surpass $252 million, exceeding prior guidance of $245 million. Diluted earnings per share (EPS) are anticipated to be over $1.38, compared to the previous estimate of $1.30. CEO Russell Low attributed the strong performance to robust demand for the Purion platform. Axcelis projects a stronger second half of 2024, with a slight emphasis on Q4. Final Q2 results will be released on July 31, 2024.
Axcelis Technologies (Nasdaq: ACLS) has announced the appointment of David Ryzhik as Senior Vice President of Investor Relations and Corporate Strategy, effective July 2024. Ryzhik brings over 20 years of experience in investor relations and finance, including roles at MKS Instruments and Susquehanna International Group. He will succeed Doug Lawson, who plans to retire but will remain as a Senior Advisor until July 2025. Lawson has had a 15-year tenure with Axcelis, holding various executive roles and significantly contributing to corporate marketing and strategy. The transition aims to leverage Ryzhik's extensive experience to further Axcelis' growth objectives.
Axcelis Technologies (NASDAQ: ACLS), a key supplier of ion implantation solutions for the semiconductor industry, has inaugurated new service offices in Chitose, Hokkaido, and Kumamoto, Kyushu, Japan. These offices, which opened in June 2024, aim to enhance support for the company's expanding customer base in Japan. Axcelis President and CEO Russell Low emphasized the company's commitment to innovation and market share growth. Charles Pieczulewski, Axcelis Japan Country Manager, noted the strategic positioning of the new offices to improve support for Purion ion implant equipment and foster relations with both Silicon (Si) and Silicon Carbide (SiC) semiconductor power device customers, enabling advancements in logic production capacity.
Axcelis Technologies (NASDAQ: ACLS) has announced its participation in the 16th Annual CEO Investor Summit 2024, scheduled for July 10th at the St. Regis Hotel in San Francisco, CA.
Axcelis, a key supplier of ion implantation solutions for the semiconductor industry, will present at the event. Presentation materials will be available on the company's investor webpage.
Axcelis Technologies (Nasdaq: ACLS) will host a hybrid Investor Event on July 11, 2024, at the St. Regis Hotel, San Francisco. The event, aimed at the investment community, will run from 8 a.m. to 11 a.m. PT, with presentations starting at 9 a.m. PT. These presentations will cover Axcelis' business, growth strategy, and financial outlook. All executive officers will be present. Interested investors can attend in person or via a live audio webcast. More details and registration links are available on Axcelis’ website.
Axcelis Technologies, Inc. (NASDAQ: ACLS) announced its participation in several upcoming investor conferences, providing a platform for management to engage with investors and discuss the company's offerings for the semiconductor industry.
Axcelis Technologies, Inc. (ACLS) announced financial results for Q1 2024, reporting revenue of $252.4 million, a gross margin of 46%, and EPS of $1.57. Despite revenue decline from the previous quarter, the company exceeded guidance and highlighted growth in the implant intensive power device segment and shipments to China. The CEO mentioned continued strong execution and product success, while the CFO emphasized robust cash flow and a positive outlook for 2024.
Summary not available.